Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

Key Points

• To determine the relationship between baseline phenotypic characteristics and the response of airway hyperresponsiveness (AHR) to biologic treatments.
• Analyzed baseline characteristics in patients receiving benralizumab and dupilumab.
• Assessed levels of FEV1 and PEF as predictors of AHR response.
• Evaluated eosinophil counts in relation to the persistence or abolition of AHR.
• Lower baseline FEV1 and PEF are linked to continued airway hyperresponsiveness.
• Higher levels of eosinophils are associated with the abolition of airway hyperresponsiveness.